Novo's CagriSema Trial Miss Meets Mixed Market Reactions

Novo Nordisk revealed disappointing results from its late-stage CagriSema trial, leading to a significant drop in its market value. The experimental obesity drug showed lower-than-expected weight loss, challenging Novo's position in the competitive anti-obesity market against rivals like Eli Lilly's Zepbound.

Novo Nordisk faced a market setback on Friday following lackluster results from its experimental CagriSema obesity drug trial. The Danish pharmaceutical giant saw its market value dip by as much as $125 billion after the drug's weight loss results fell below expectations.

The CagriSema trial, a crucial indicator for Novo's drug pipeline, showed a 22.7% weight loss among participants—short of the anticipated 25%. This setback comes amid fierce competition in the anti-obesity market dominated by rivals such as Eli Lilly’s Zepbound.

As shares plummeted by up to 27%, investors and analysts highlighted the complexity of manufacturing CagriSema compared to Zepbound. Despite the disappointment, Novo remains optimistic, planning further trials and regulatory submission for CagriSema by 2025.